RizLab Health

Executive Summary

RizLab Health is a US-based diagnostics company developing the CytoTracker, a handheld point-of-care white blood cell (WBC) analyzer. The device leverages microfluidics and artificial intelligence to deliver accurate WBC counts from a single drop of blood in under six minutes. By enabling rapid, decentralized infection screening, CytoTracker aims to improve triage in emergency and urgent care settings, accelerate treatment decisions, and reduce antibiotic misuse. Founded in 2020 and based in San Francisco, the company addresses a critical need for faster, more accessible diagnostics to combat antimicrobial resistance and optimize patient outcomes. The global point-of-care diagnostics market is growing rapidly, and RizLab Health's focus on WBC analysis positions it uniquely against traditional lab-based hematology analyzers. The CytoTracker's speed and portability offer significant advantages in time-sensitive environments. While the company is private with undisclosed funding and valuation, its technology has the potential to disrupt standard infection screening. Key risks include regulatory hurdles, competition from established players, and the need for clinical validation. Overall, RizLab Health represents a promising but early-stage opportunity in decentralized diagnostics.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance60% success
• Q2 2026Clinical Study Results Showing Non-Inferiority70% success
• Q1 2027Commercial Partnership with Hospital Network50% success